Calendar

Week of Apr 27, 2026

Apr 30, 2026phase 1 2 completion84d agoAmsterdam UMC — tremelimumab (Phase I/II Trial Completion)tremelimumab

Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

full page →tremelimumab →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoInstitute of Hematology & Blood Diseases Hospital — cyclophosphamide (Phase I/II Trial Completion)cyclophosphamide

Therapy area: Oncology. Indication: B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)

full page →cyclophosphamide →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoZhejiang Doer Biologics Corp — DR-30206 (Phase I/II Trial Completion)DR-30206

Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Colorectal Cancer, Gastrointestinal Tumor, Metastatic Colorectal Cancer

full page →DR-30206 →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoUniversity Hospital Geneva — verteporfin (Phase I/II Trial Completion)verteporfin

Therapy area: Dermatology, Infectious Disease, Oncology. Indication: Melanoma, Scar, Surgical Wound Infections

full page →verteporfin →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoLepu Biopharma Co Ltd — pucotenlimab (Phase I/II Trial Completion)pucotenlimab

Therapy area: Oncology. Indication: Pancreatic Cancer

full page →pucotenlimab →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoJiangsu Hengrui Pharmaceuticals Co Ltd — adebrelimab (Phase I/II Trial Completion)adebrelimab

Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

full page →adebrelimab →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoMultitude therapeutics Inc — AMT-253 (Phase I/II Trial Completion)AMT-253

Therapy area: Non Malignant Disorders, Oncology. Indication: Acral Lentiginous Melanoma, Cervical Cancer, Endometrial Cancer, Gynecological Cancer, Leiomyosarcoma, Melanoma, Metastatic Melanoma, Solid Tumor, Uterine Leiomyoma (Uterine Fibroids)

full page →AMT-253 →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoBayer AG — avelumab (Phase I/II Trial Completion)avelumab

Therapy area: Oncology. Indication: Bone Metastasis, Malignant Neoplasms, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostate Cancer

full page →avelumab →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoAbbVie Inc — venetoclax (Phase I/II Trial Completion)venetoclax

Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Leukemia, Leukemia, T-Cell Leukemia

full page →venetoclax →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoAstraZeneca Plc — Calquence (Phase I/II Trial Completion)CALQUENCE

Therapy area: Oncology. Indication: CNS Lymphoma, Diffuse Large B-Cell Lymphoma, Primary CNS Lymphoma, Secondary CNS Lymphoma

full page →CALQUENCE →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoHenan Cancer Hospital — methotrexate (Phase I/II Trial Completion)Maxtrex

Therapy area: Oncology. Indication: Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Lung Cancer

full page →Maxtrex →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoArvinas Inc — samuraciclib (Phase I/II Trial Completion)samuraciclib

Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer

full page →samuraciclib →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoChiba Cancer Center — nivolumab (Phase I/II Trial Completion)nivolumab

Therapy area: Oncology. Indication: Adenoid Squamous Cell Carcinoma (Pseudoglandular Squamous Cell Carcinoma), Basaloid Squamous Cell Carcinoma, Esophageal Cancer, Squamous Cell Carcinoma

full page →nivolumab →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoNational Cheng-Kung University Hospital — cisplatin (Phase I/II Trial Completion)cisplatin

Therapy area: Oncology. Indication: Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC)

full page →cisplatin →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoWuhan YZY Biopharma Co Ltd — M-701 (Phase I/II Trial Completion)M-701

Therapy area: Oncology, Respiratory. Indication: Malignant Pleural Effusion, Non-Small Cell Lung Cancer

full page →M-701 →source: globaldata

Apr 30, 2026phase 1 2 initiation84d agoNational Cancer Institute US — PEP-CMV (Phase I/II Trial Initiation)PEP-CMV

Therapy area: Oncology. Indication: Ependymoma, Glioma, High-Grade Glioma, Medulloblastoma

full page →PEP-CMV →source: globaldata

Apr 30, 2026phase 1 2 initiation84d agoSichuan Kelun Pharmaceutical Co Ltd — SKB-103 (Phase I/II Trial Initiation)SKB-103

Therapy area: Oncology. Indication: Solid Tumor

full page →SKB-103 →source: globaldata

Apr 30, 2026phase 1 2 initiation84d agoRemeGen Co Ltd — RC-288 (Phase I/II Trial Initiation)RC-288

Therapy area: Oncology. Indication: Melanoma, Non-Small Cell Lung Cancer, Prostate Cancer, Small-Cell Lung Cancer, Solid Tumor

full page →RC-288 →source: globaldata

Apr 30, 2026phase 1 2 initiation84d agoFennec Pharmaceuticals Inc — sodium thiosulfate (Phase I/II Trial Initiation)sodium thiosulfate

Therapy area: Ear Nose Throat Disorders, Oncology. Indication: Esophageal Cancer, Head And Neck Cancer, Hearing Disorders, Lung Cancer, Malignant Pleural Mesothelioma, Solid Tumor, Testicular Cancer, Thymoma (Thymic Epithelial Tumor)

full page →sodium thiosulfate →source: globaldata

Apr 30, 2026phase 1 2 initiation84d agoDartsbio Pharmaceutical (Guangdong) Co Ltd — DS-010 (Phase I/II Trial Initiation)DS-010

Therapy area: Musculoskeletal Disorders, Oncology. Indication: Cachexia, Cancer Anorexia-Cachexia Syndrome, Solid Tumor

full page →DS-010 →source: globaldata

Apr 30, 2026phase 1 2 initiation84d agoInstitute of Hematology & Blood Diseases Hospital — azacitidine (Phase I/II Trial Initiation)Onureg

Therapy area: Oncology. Indication: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Myelodysplastic Syndrome (Preleukemia)

full page →Onureg →source: globaldata

Apr 30, 2026phase 1 2 initiation84d agoBeijing Bethune Charitable Foundation — bevacizumab (Phase I/II Trial Initiation)bevacizumab

Therapy area: Oncology. Indication: Hepatocellular Carcinoma

full page →bevacizumab →source: globaldata

Apr 30, 2026phase 1 2 initiation84d agoBeijing Eastern Biotech Co Ltd — JY-016 (Phase I/II Trial Initiation)JY-016

Therapy area: Oncology. Indication: Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Recurrent Head And Neck Squamous Cell Carcinoma, Solid Tumor

full page →JY-016 →source: globaldata

Apr 30, 2026phase 1 2 initiation84d agoCompass Therapeutics Inc — CTX-471 (Phase I/II Trial Initiation)CTX-471

Therapy area: Oncology. Indication: Glioblastoma Multiforme (GBM), Glioma, Recurrent Glioblastoma Multiforme (GBM)

full page →CTX-471 →source: globaldata

Apr 30, 2026phase 2 completion84d agoGandhi Medical College & Hospital — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

Therapy area: Oncology. Indication: Malignant Neoplasms

full page →dexmedetomidine →source: globaldata

Apr 30, 2026phase 2 completion84d agoQilu Pharmaceutical Co Ltd — iruplinalkib (Phase II Trial Completion)iruplinalkib

Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

full page →iruplinalkib →source: globaldata

Apr 30, 2026phase 2 completion84d agoRegeneron Pharmaceuticals Inc — cemiplimab (Phase II Trial Completion)cemiplimab

Therapy area: Oncology. Indication: Adenocarcinoma, Colon Cancer, Colorectal Cancer

full page →cemiplimab →source: globaldata

Apr 30, 2026phase 2 completion84d agoIntas Pharmaceuticals Ltd — olaparib (Phase II Trial Completion)olaparib

Therapy area: Oncology. Indication: Breast Cancer, Castration-Resistant Prostate Cancer (CRPC), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Peritoneal Cancer, Solid Tumor

full page →olaparib →source: globaldata

Apr 30, 2026phase 2 completion84d agoMerck & Co Inc — pembrolizumab (Phase II Trial Completion)pembrolizumab

Therapy area: Oncology. Indication: Glioblastoma Multiforme (GBM), Gliosarcoma

full page →pembrolizumab →source: globaldata

Apr 30, 2026phase 2 completion84d agoAustralasian Gastro-Intestinal Trials Group — valproate sodium (Phase II Trial Completion)VALPROATE SODIUM

Therapy area: Oncology. Indication: Colorectal Cancer, Metastatic Colorectal Cancer

full page →VALPROATE SODIUM →source: globaldata

Apr 30, 2026phase 2 completion84d agoZhejiang University Hospital One — serplulimab (Phase II Trial Completion)serplulimab

Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Gastric Cancer

full page →serplulimab →source: globaldata

Apr 30, 2026phase 2 completion84d agoGuangzhou Panyu Central Hospital — aumolertinib mesylate (Phase II Trial Completion)aumolertinib mesylate

Therapy area: Oncology. Indication: Lung Adenocarcinoma, Non-Small Cell Lung Cancer

full page →aumolertinib mesylate →source: globaldata

Apr 30, 2026phase 2 completion84d agoSun Yat-Sen University Hospital 5 — carboplatin (Phase II Trial Completion)Carboplatin Pfizer

Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

full page →Carboplatin Pfizer →source: globaldata

Apr 30, 2026phase 2 completion84d agoShanghai Longfine Biotechnology Co Ltd — toripalimab (Phase II Trial Completion)toripalimab

Therapy area: Oncology. Indication: Triple-Negative Breast Cancer (TNBC)

full page →toripalimab →source: globaldata

Apr 30, 2026phase 2 completion84d agoCancer Institute and Hospital Chinese Academy of Medical Sciences — lenvatinib (Phase II Trial Completion)lenvatinib

Therapy area: Cardiovascular, Oncology. Indication: Hepatocellular Carcinoma, Thrombosis, Venous (Vein) Thrombosis

full page →lenvatinib →source: globaldata

Apr 30, 2026phase 2 completion84d agoMedical University of Gdansk — apixaban (Phase II Trial Completion)apixaban ODT

Therapy area: Cardiovascular, Oncology. Indication: Diffuse Large B-Cell Lymphoma, Hematological Tumor, Leukemia, Lymphoma, Multiple Myeloma (Kahler Disease), Myeloproliferative Disorders, Pulmonary Embolism, Thromboembolic Disease, Venous Thromboembolism

full page →apixaban ODT →source: globaldata

Apr 30, 2026phase 2 completion84d agoXijing Hospital — pertuzumab + trastuzumab (Phase II Trial Completion)pertuzumab + trastuzumab

Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Triple-Negative Breast Cancer (TNBC)

full page →pertuzumab + trastuzumab →source: globaldata

Apr 30, 2026phase 2 completion84d agoBeijing Sanbo Brain Hospital — ceritinib (Phase II Trial Completion)ceritinib

Therapy area: Oncology. Indication: Mesenchymal Tumor

full page →ceritinib →source: globaldata

Apr 30, 2026phase 2 completion84d agoWuhan Union Hospital — cadonilimab (Phase II Trial Completion)cadonilimab

Therapy area: Oncology. Indication: Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC)

full page →cadonilimab →source: globaldata

Apr 30, 2026phase 2 completion84d agoOhio State University Comprehensive Cancer Center — canakinumab (Phase II Trial Completion)canakinumab

Therapy area: Oncology. Indication: Lung Cancer

full page →canakinumab →source: globaldata

Apr 30, 2026phase 2 completion84d agoNational Cancer Institute US — ipilimumab (Phase II Trial Completion)ipilimumab

Therapy area: Oncology. Indication: Endometrial Cancer

full page →ipilimumab →source: globaldata

Apr 30, 2026phase 2 completion84d agoBioCanRx — ipilimumab (Phase II Trial Completion)ipilimumab

Therapy area: Oncology. Indication: Kidney Cancer (Renal Cell Cancer), Metastatic Renal Cell Carcinoma

full page →ipilimumab →source: globaldata

Apr 30, 2026phase 2 completion84d agoChinese Academy of Medical Sciences and Peking Union Medical College — fuzuloparib (Phase II Trial Completion)fuzuloparib

Therapy area: Oncology. Indication: Soft Tissue Sarcoma

full page →fuzuloparib →source: globaldata

Apr 30, 2026phase 2 completion84d agoSun Pharmaceutical Industries Ltd — Absorica (Phase II Trial Completion)ISOTRETINOIN

Therapy area: Oncology. Indication: Neuroblastoma

full page →ISOTRETINOIN →source: globaldata

Apr 30, 2026phase 2 completion84d agoArcus Biosciences Inc — atezolizumab (Phase II Trial Completion)atezolizumab

Therapy area: Oncology. Indication: Prostate Cancer

full page →atezolizumab →source: globaldata

Apr 30, 2026phase 2 completion84d agoHospital Of Dalian Medical University 1 — adebrelimab (Phase II Trial Completion)adebrelimab

Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Gastric Cancer

full page →adebrelimab →source: globaldata

Apr 30, 2026phase 2 completion84d agoCancer Institute and Hospital Chinese Academy of Medical Sciences — capecitabine (Phase II Trial Completion)capecitabine

Therapy area: Oncology. Indication: Colorectal Cancer

full page →capecitabine →source: globaldata

Apr 30, 2026phase 2 completion84d agoNanfang Hospital of Southern Medical University — adebrelimab (Phase II Trial Completion)adebrelimab

Therapy area: Oncology. Indication: Small-Cell Lung Cancer

full page →adebrelimab →source: globaldata

← prev

page 3 of 3

Week of Apr 27, 2026